-
Zhonghua Xue Ye Xue Za Zhi = Zhonghua... Jan 2019To analyze the clinical outcome and the prognostic factor in pediatric patients with core binding factor-acute myeloid leukemia (CBF-AML). A total of 121 newly...
To analyze the clinical outcome and the prognostic factor in pediatric patients with core binding factor-acute myeloid leukemia (CBF-AML). A total of 121 newly diagnosed pediatric CBF-AML patients enrolled from Aug. 2005 to Sep. 2017 were retrospectively reviewed. Cumulative incidence of relapse (CIR), event-free survival (EFS) and overall survival (OS) rates were estimated by Kaplan-Meier method and prognostic factors were evaluated by Cox regression with SPSS. Of the 121 patients, 120 patients were assessed for bone marrow remission after induction chemotherapy. 100 cases (83.3%) achieved complete remission (CR) after the first course of chemotherapy. 119 cases (99.2%) achieved CR after the second course of chemotherapy. Of the 121 patients, 13 patients (10.7%) had recurrence with the median interval of recurrence as 13.8 months (3.7 to 58.8 months). 17 patients (14.0%) died. The CIR, EFS and OS at 3 years were 12.7%, 77.5% and 82.8%, respectively. The factors including age at diagnosis, sex, initial WBC count, presence of extramedullary leukemia, C-KIT expression, additional chromosomal abnormalities, and CR after the first course of chemotherapy were analyzed by multivariate regression analysis of Cox. Multivariate analysis identified that additional chromosomal abnormalities was the only independent risk factor affecting OS (=4.289, 95% 1.070-17.183, =0.040). Pediatric CBF-AML was a unique setting of prognostic subtypes. Chemotherapy produced good responses. Additional chromosomal abnormalities was the only independent risk factor for OS in pediatric CBF-AML.
Topics: Child; Core Binding Factors; Disease-Free Survival; Humans; Leukemia, Myeloid, Acute; Prognosis; Remission Induction; Retrospective Studies
PubMed: 30704229
DOI: 10.3760/cma.j.issn.0253-2727.2019.01.010 -
Expert Review of Anticancer Therapy Dec 2019: Recent advances in diagnostic modalities and therapeutic agents have raised the importance of prognostic factors in predicting overall survival, as well as predictive... (Review)
Review
: Recent advances in diagnostic modalities and therapeutic agents have raised the importance of prognostic factors in predicting overall survival, as well as predictive factors for surgical outcomes, in tailoring therapeutic strategies of patients with pancreatic neuroendocrine neoplasms (panNENs).: Numerous recent studies of panNEN patients report the prognostic values of a number of clinically related factors (clinical, laboratory, imaging, treatment-related factors), pathological factors (histological, classification, grading) and molecular factors on long-term survival. In addition, an increasing number of studies showed the usefulness of various factors, specifically biomarkers and molecular makers, in predicting recurrence and mortality related to surgical treatment. Recent findings (from the last 3 years) in each of these areas, as well as recent controversies, are reviewed.: The clinical importance of prognostic and predictive factors for panNENs is markedly increased for both overall outcome and post resection, as a result of recent advances in all aspects of the diagnosis, management and treatment of panNENs. Despite the proven prognostic utility of routinely used tumor grading/classification and staging systems, further studies are required to establish these novel prognostic factors to support their routine clinical use.
Topics: Biomarkers, Tumor; Humans; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Neuroendocrine Tumors; Pancreatic Neoplasms; Prognosis; Survival Rate
PubMed: 31738624
DOI: 10.1080/14737140.2019.1693893 -
The Oncologist Nov 2020This letter to the editor responds to remarks on the authors' recently published article on the role of HER2 as a negative prognostic factor in completely resected...
This letter to the editor responds to remarks on the authors' recently published article on the role of HER2 as a negative prognostic factor in completely resected biliary tract cancer.
Topics: Biliary Tract Neoplasms; Humans; Prognosis
PubMed: 32969114
DOI: 10.1002/onco.13538 -
International Journal of Surgery... Aug 2019
Topics: Albumins; Alkaline Phosphatase; Humans; Lung Neoplasms; Prognosis; Propensity Score; Prospective Studies
PubMed: 31336171
DOI: 10.1016/j.ijsu.2019.07.015 -
[Rinsho Ketsueki] the Japanese Journal... 2020Minimal (measurable) residual disease (MRD) in acute leukemia denotes the presence of leukemic cells detected by multiparameter flow cytometry or various molecular... (Review)
Review
Minimal (measurable) residual disease (MRD) in acute leukemia denotes the presence of leukemic cells detected by multiparameter flow cytometry or various molecular techniques in patients achieving hematological remission. The MRD become an independent, post-diagnosis, prognostic indicator important for risk stratification and treatment planning, in conjunction with other well-established clinical, cytogenetic, and molecular data assessed at diagnosis in acute myeloid leukemia (AML). However, several issues remain with regard to the ideal time point to measure MRD, the clinically significant threshold, the sample (peripheral blood or bone marrow) should be used, and the standardize tests, so that results from different laboratories become comparable. This review gives an overview of the currently available evidence regarding technical issues, prognostic impact, and MRD-directed treatment for AML.
Topics: Bone Marrow; Flow Cytometry; Humans; Leukemia, Myeloid, Acute; Neoplasm, Residual; Prognosis
PubMed: 32378579
DOI: 10.11406/rinketsu.61.343 -
Clinical and Translational Science Jun 2022The exact role of pleural effusion in the prognosis of cancer patients remains unclear. We aimed to systematically review the prognostic value of pleural effusion in... (Meta-Analysis)
Meta-Analysis Review
The exact role of pleural effusion in the prognosis of cancer patients remains unclear. We aimed to systematically review the prognostic value of pleural effusion in patients with cancer. We performed a systematic review and meta-analysis with a systematic literature search. All cohort studies with available overall survival (OS) and progression-free survival (PFS) results for patients with cancer with or without pleural effusion were included. The Mantel-Haenszel method was used to calculate the pooled hazard ratios (HRs) and 95% confidence intervals (CIs). Heterogeneity and publication bias were examined. Subgroup analysis and sensitivity analysis were performed. A total of 47 studies with 146,117 patients were included in the analysis. For OS, pleural effusion was a prognostic factor associated with a poor prognosis for patients with cancer (HR, 1.58, 95% CI, 1.43-1.75; I 94.8%). In the subgroup analysis, pleural effusion was a prognostic factor associated with poor survival for patients with lung cancer (HR, 1.44, 95% CI, 1.35-1.54; I 60.8%), hematological cancer (HR, 2.79, 95% CI, 1.63-4.77; I 29.4%) and other types of cancer (HR, 2.08, 95% CI, 1.43-3.01; I 55.1%). For PFS, pleural effusion was a prognostic factor associated with a poor prognosis for patients with cancer (HR, 1.61, 95% CI, 1.28-2.03; I 42.9%). We also observed that massive pleural effusion was a prognostic factor associated with a poorer prognosis compared to minimal pleural effusion. Pleural effusion had prognostic value in both OS and PFS of patients with cancer, except for patients with malignant pleural mesothelioma, regardless of whether the malignant effusion was confirmed histologically or cytologically. However, future evidence of other pleural effusion characteristics is still needed.
Topics: Humans; Lung Neoplasms; Mesothelioma, Malignant; Pleural Effusion; Prognosis; Proportional Hazards Models
PubMed: 35212454
DOI: 10.1111/cts.13260 -
Gastroenterology Apr 2020
Topics: Anticoagulants; Humans; Incidence; Neoplasms; Pancreatic Neoplasms; Prognosis; Venous Thromboembolism
PubMed: 32061863
DOI: 10.1053/j.gastro.2020.02.017 -
Annals of Surgical Oncology Jul 2023
Topics: Humans; Thymoma; Prognosis; Thymus Neoplasms; Neoplasm Staging; Retrospective Studies
PubMed: 37067743
DOI: 10.1245/s10434-023-13445-z -
Annals of Medicine Dec 2023Anesthetic drugs had been reported may impact the bio-behavior of the tumor. Propofol and sevoflurane are common anesthetics in the operation for glioblastoma (GBM)....
OBJECTIVES
Anesthetic drugs had been reported may impact the bio-behavior of the tumor. Propofol and sevoflurane are common anesthetics in the operation for glioblastoma (GBM). This study aims to establish a co-expression prognostic-related genes signature base on propofol and sevoflurane anesthesia to predict prognosis and immunotherapy response in GBM.
METHOD
GPM tissues with different anesthetics gene expression profiles (GSE179004) were obtained from the Gene Expression Omnibus (GEO) database. Core modules and central genes associated with propofol and sevoflurane anesthesia were identified by weighted gene coexpression network analysis (WGCNA) and establish a risk score prognostic model. Immune cell signature analysis in TCGA datasets was predicted via CIBERSORT. At last, serum methylation level of O6-methylguanine-DNA methyltransferase (MGMT) promoter was detected in GPM patient in different time during perioperative period.
RESULTS
The burlywood1 group screened was significantly associated with sevoflurane-treated GBM tissue. 22 independent prognostic differential genes were construct a prognostic-related genes risk score in GBM, and showed good predictive ability. The risk score was strongly correlated with the age of the patients, but not with the sex of the patients. In addition, the differential responses to immunotherapy in high and low risk groups were analyzed, indicating that sevoflurane signature genes were consistent in the classification of gliomas. High-risk patients have high T-cell damage score and are less sensitive to immunotherapy. At last, serum methylation level of MGMT promoter was decreased in GBM patients during propofol and sevoflurane anesthesia.
CONCLUSIONS
Propofol and sevoflurane anesthesia associated impact on the gene expression of GBM, included the methylation level of MGMT promoter. Propofol and sevoflurane anesthesia-based risk score prognostic model, which has good prognostic power and is an independent prognostic factor in GBM patients. Therefore, this model can be used as a new biomarker for judging the prognosis of GBM patients.KEY MESSAGESPropofol and sevoflurane anesthesia-based risk score prognostic model has good prognostic power and is an independent prognostic factor in GBM patients.High Propofol and sevoflurane anesthesia-based risk score GBM patients have high T-cell damage scores and are less sensitive to immunotherapy.Serum methylation level of MGMT promoter decrease during propofol and sevoflurane anesthesia in GBM patients.
Topics: Humans; Glioblastoma; Propofol; Sevoflurane; Prognosis; Anesthesia; Immunotherapy
PubMed: 36856519
DOI: 10.1080/07853890.2023.2171109 -
Oral Oncology Jan 2020Oral cavity cancers are treated by surgery with or without adjuvant therapy. Being the most important prognostic factor, neck node management is an important aspect of... (Review)
Review
Oral cavity cancers are treated by surgery with or without adjuvant therapy. Being the most important prognostic factor, neck node management is an important aspect of treating oral cancers. There are numerous areas of debate in the management of the node-negative and node-positive neck. In an attempt to answer these questions, a large volume of literature has been generated over the last few decades. This review article describes the current evidence and approach considerations for the management of cervical nodes in patients with oral cavity cancers.
Topics: Humans; Lymph Node Excision; Lymphatic Metastasis; Mouth Neoplasms; Neck Dissection; Prognosis; Prophylactic Surgical Procedures; Treatment Outcome
PubMed: 31790914
DOI: 10.1016/j.oraloncology.2019.104476